influenza
viru
notori
known
abil
caus
recurr
epidem
global
pandem
antivir
therapi
effect
treatment
initi
within
h
symptom
onset
delay
treatment
beyond
time
frame
associ
decreas
efficaci
research
antiinflammatori
therapi
amelior
influenzainduc
inflamm
current
underway
seem
import
impact
clinic
outcom
antivir
antiinflammatori
drug
novel
mechan
action
urgent
need
current
method
evalu
efficaci
antiinfluenza
drug
reli
mostli
transform
cell
anim
transform
cell
model
distantli
relat
physiolog
patholog
condit
although
anim
best
choic
preclin
drug
test
timeor
costeffici
studi
establish
ex
vivo
model
use
mous
lung
slice
evalu
antivir
antiinflammatori
agent
influenza
viru
infect
influenza
viru
replic
effici
mous
lung
slice
trigger
signific
cytokin
chemokin
respons
induct
select
cytokin
chemokin
found
posit
correl
ex
vivo
vivo
experi
suggest
ex
vivo
cultur
lung
slice
may
close
resembl
lung
function
vivo
configur
challeng
influenza
viru
furthermor
set
agent
known
antivir
andor
antiinflammatori
activ
test
valid
ex
vivo
model
result
suggest
mous
lung
slice
provid
robust
conveni
costeffici
model
assess
antivir
antiinflammatori
agent
influenza
viru
infect
one
assay
ex
vivo
model
may
predict
efficaci
drug
candid
antivir
antiinflammatori
activ
vivo
influenza
viru
iav
still
threat
human
health
pose
global
concern
due
unpredict
pandem
potenti
pathogenesi
high
evolutionari
rate
influenza
viru
make
vaccin
strategi
difficult
antiinfluenza
drug
crucial
control
influenza
pandem
antivir
therapi
gener
licens
use
within
h
influenza
ill
onset
delay
treatment
associ
decreas
drug
efficaci
increas
morbid
mortal
kandun
et
al
although
influenzainduc
patholog
still
unclear
uncontrol
immun
respons
may
major
contributor
influenza
virusinduc
mortal
de
jong
et
al
iwasaki
medzhitov
kobasa
et
al
thu
studi
modul
host
immun
respons
current
underway
sever
anim
studi
shown
antiinflammatori
agent
http
elsevi
bv
right
reserv
abbrevi
tnfa
tumour
necrosi
factor
alpha
interleukin
rant
regul
activ
normal
cell
express
secret
macrophag
inflammatori
protein
alpha
interferongamma
induc
protein
interleukin
interleukin
beta
ifnc
interferon
gamma
pparc
peroxisom
proliferatoractiv
receptor
gamma
egcg
epigallocatechin
gallat
chemokin
cxc
motif
receptor
tumour
necrosi
factor
alpha
receptor
interleukin
receptor
macrophag
inflammatori
protein
cc
chemokin
receptor
type
gmcsf
granulocytemacrophag
colonystimul
factor
ip
intraperiton
balf
bronchoalveolar
lavag
fluid
rigi
retino
acidinduc
gene
tlr
tolllik
receptor
tlr
tolllik
receptor
munana
adacetylneuramin
acid
protect
mice
death
influenza
infect
prostaglandin
j
shown
protect
mice
death
lethal
influenza
infect
manipul
pparc
pathway
wherea
inhibit
viru
replic
cloutier
et
al
inhibitor
significantli
protect
mice
lethal
influenza
infect
without
affect
viru
replic
borgel
et
al
statin
reduc
level
ldlcholesterol
also
counteract
inflammatori
chang
associ
acut
coronari
syndrom
improv
surviv
patient
influenza
similarli
patient
hospitalis
laboratoryconfirm
season
influenza
statin
treatment
associ
reduct
mortal
fedson
therefor
strategi
target
aberr
host
immun
respons
may
good
complement
exist
antivir
drug
routin
strategi
antiinfluenza
drug
develop
reli
primarili
cellbas
assay
primari
screen
follow
anim
studi
howev
cost
vivo
studi
high
due
use
anim
larg
quantiti
investig
compound
lung
slice
provid
bridg
singl
cell
whole
anim
broadli
use
physiolog
toxic
studi
morin
et
al
sanderson
differ
singl
cell
line
lung
slice
possess
multipl
cell
type
preserv
physiolog
function
cellular
relationship
within
bodi
cellcel
cellmatrix
interact
result
lung
slice
close
resembl
morpholog
function
lung
wherea
evalu
efficaci
drug
base
anim
studi
expens
timeconsum
lung
slice
model
may
serv
valuabl
tool
efficaci
test
compound
treatment
influenza
develop
tissu
slicer
produc
slice
rapidli
reproduc
increas
number
studi
employ
lung
slice
explor
interact
host
pathogen
chakrabarti
et
al
londt
et
al
punyadarsaniya
et
al
seehas
et
al
van
pouck
et
al
wu
et
al
recent
sever
studi
shown
pig
lung
slice
support
influenza
viru
replic
londt
et
al
van
pouck
et
al
anoth
studi
demonstr
influenza
viru
infect
induc
robust
cytokin
chemokin
respons
human
lung
slice
wu
et
al
theoret
threedimension
lung
slice
cultur
system
use
evalu
potenc
antivir
antiinflammatori
agent
influenza
viru
infect
current
studi
show
influenza
virus
effici
replic
mous
lung
slice
induc
significantli
elev
level
cytokin
chemokin
panel
antivir
antiinflammatori
agent
test
antivir
activ
andor
antiinflammatori
effect
mous
lung
slice
result
lung
slice
model
consist
mous
studi
result
show
lung
slice
model
provid
robust
conveni
costeconom
method
screen
evalu
antivir
antiinflammatori
agent
influenza
viru
infect
one
assay
old
balbc
mice
purchas
changsha
laboratori
anim
center
hunan
provinc
china
hous
specificpathogenfre
condit
experi
conduct
accord
protocol
approv
anim
care
use
committe
wuhan
institut
virolog
chines
academi
scienc
mous
adapt
mous
adapt
propag
allanto
caviti
specificpathogenfre
embryon
chicken
egg
h
allanto
fluid
collect
filter
lm
filter
store
viru
strain
provid
viru
collect
wuhan
institut
virolog
chines
academi
scienc
china
prostaglandin
j
ribavirin
neuraminidas
substrat
adacetylneuramin
acid
munana
purchas
sigmaaldrich
egcg
purchas
sichuang
weikeqi
biolog
technolog
co
ltd
china
glycyrrhizin
purchas
shanghai
hanxiang
biolog
technolog
co
ltd
china
pathway
inhibitor
erk
pathway
inhibitor
sapkjnk
pathway
inhibitor
purchas
beyotim
institut
biotechnolog
china
oseltamivir
carboxyl
gs
obtain
toronto
research
chemic
canada
compound
initi
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
mous
lung
slice
prepar
use
modif
protocol
previous
report
bauer
et
al
anesthetis
intraperiton
inject
sodium
pentobarbit
mgkg
mous
bled
abdomin
aorta
trachea
expos
dissect
surround
tissu
cannul
needl
cannula
lung
inflat
ml
lowmelt
agaros
biorad
dissolv
hank
buffer
salin
solut
hbss
solut
whole
anim
cool
ice
min
solidifi
agaros
therebi
lung
lung
taken
en
bloc
thorac
caviti
place
slice
cultur
medium
dulbecco
modifi
eagl
medium
nutrient
mixtur
gibco
addit
min
complet
solidifi
agaros
cultur
medium
supplement
unitsml
penicillin
lgml
streptomycin
ngml
amphotericin
avoid
contamin
lung
lobe
afterward
dissect
cut
creat
flat
surfac
end
primari
bronchu
anoth
flat
surfac
cut
approxim
cm
first
surfac
cube
maintain
prechil
slice
cultur
medium
prior
slice
cube
cut
slice
desir
thick
use
vibratom
slicer
leica
mous
lung
cube
gener
least
slice
slice
transfer
cell
cultur
plate
cover
slice
cultur
medium
well
medium
chang
everi
hour
least
three
time
viru
infect
remov
cell
debri
lung
slice
viabil
assess
bronchoconstrict
livedead
stain
bronchoconstrict
monitor
microscop
ad
remov
chlorid
sigmaaldrich
photo
taken
use
nikon
invert
research
microscop
ti
eclips
livedead
stain
experi
slice
incub
calcein
lm
propidium
iodid
pi
lgml
min
room
temperatur
nikon
multiphoton
confoc
microscop
mp
use
record
imag
lung
slice
infect
pfuml
influenza
virus
h
viru
diluent
use
neg
control
incub
virus
discard
slice
wash
twice
phosphat
buffer
salin
pb
fresh
medium
ad
indic
time
point
supernat
harvest
viru
titr
express
level
cytokin
chemokin
detect
slice
store
rna
extract
perform
drug
addit
assay
lung
slice
prepar
describ
section
last
wash
slice
infect
pfuml
viru
incub
h
viru
discard
slice
wash
pb
measur
z
factor
plate
one
lung
slice
per
well
process
follow
one
column
uninfect
one
column
infect
mock
treat
rest
column
infect
treat
six
concentr
dilut
ribavirin
start
lm
total
four
plate
process
lung
slice
model
valid
assay
plate
contain
two
agent
data
point
three
lung
slice
na
activ
level
determin
h
post
infect
viru
titr
determin
tcid
assay
briefli
madindarbi
canin
kidney
mdck
cell
maintain
dmem
supplement
foetal
bovin
serum
unitsml
penicillinstreptomycin
mdck
cell
seed
cell
cultur
plate
twentyfour
hour
later
serial
dilut
supernat
inocul
mdck
monolay
h
cytopath
effect
examin
viru
titr
calcul
reedmuench
method
reed
muench
adacetylneuramin
acid
munana
fluorometr
substrat
neuraminidas
influenza
viru
viru
contain
sampl
mix
lm
munana
dissolv
me
solut
mm
nmorpholino
ethanesulfon
acid
mm
cacl
ph
incub
h
black
optipl
perkinelm
reaction
stop
ad
naoh
ethanol
fluoresc
signal
record
nm
excit
nm
emiss
use
wallac
envis
multilabel
reader
perkinelm
protein
level
tnfa
ifnc
rant
measur
use
commerci
elisa
kit
boster
biotechnolog
compani
wuhan
china
antiinflammatori
assay
use
readout
protein
level
measur
use
duoset
elisa
develop
kit
r
drug
toxic
assess
mtt
assay
slice
incub
serial
dilut
concentr
drug
h
drug
remov
slice
wash
pb
incub
mtt
mgml
min
formazan
complet
dissolv
dmso
dmso
solut
transfer
plate
optic
densiti
od
dissolv
formazan
measur
nm
lm
thick
lung
slice
cut
expos
pfuml
hubei
virus
incub
h
virus
remov
fresh
medium
ad
h
later
slice
fix
paraformaldehyd
h
room
temperatur
slice
incub
block
buffer
pb
contain
bsa
triton
normal
goat
serum
anoth
h
afterward
slice
immunoprob
antibodi
nucleoprotein
influenza
viru
santa
cruz
bind
buffer
pb
contain
bsa
triton
overnight
wash
three
time
pb
slice
incub
dapi
lgml
sigmaaldrich
tritcconjug
goat
antimous
igg
h
fluoresc
imag
obtain
use
nikon
multiphoton
confoc
microscop
mp
nikon
total
rna
extract
lung
slice
microelut
total
rna
kit
accord
anim
tissu
protocol
omega
revers
transcript
conduct
use
random
hexam
primer
realtim
quantit
pcr
perform
use
univers
sybr
green
supermix
biorad
pcr
condit
cycl
primer
cytokin
chemokin
synthesis
accord
previous
publish
data
giulietti
et
al
mice
anesthet
intraperiton
inject
sodium
pentobarbit
mgkg
twenti
microlitr
pfuml
viru
inocul
nasal
mock
group
inocul
viru
diluent
day
post
infect
mock
mice
infect
mice
sacrif
trachea
lung
remov
wash
three
time
inject
ml
pb
contain
bsa
centrifug
rpm
bronchoalveolar
lavag
fluid
balf
store
statist
analysi
perform
unpair
ttest
correl
cytokineschemokin
ex
vivo
vivo
evalu
use
linear
regress
analysi
use
graphpad
prism
softwar
cc
ec
valu
determin
use
nonlinear
regress
use
graphpad
prism
statist
signific
determin
follow
p
p
data
figur
repres
mean
sem
z
factor
calcul
accord
method
describ
previous
zhang
et
al
establish
ex
vivo
lung
slice
model
influenza
viru
infect
viabil
lung
slice
must
maintain
first
test
long
mous
lung
slice
remain
viabl
ex
vivo
cultur
condit
mous
lung
slice
viabil
assess
base
bronchoconstrict
assay
livedead
viabil
assay
shown
fig
strong
bronchoconstrict
compar
b
could
induc
day
data
shown
treatment
lm
chlorid
remov
drug
result
relax
airway
fig
assess
viabil
lung
slice
livedead
stain
method
use
evalu
whether
alveolar
architectur
remain
intact
aliv
prepar
ex
vivo
cultur
shown
fig
slice
almost
green
viabl
cell
directli
prepar
fig
wherea
treatment
slice
result
red
nuclei
stain
dead
cell
fig
addit
mous
lung
slice
stay
aliv
alveolar
architectur
lung
slice
remain
intact
day
prepar
fig
collect
result
suggest
mous
lung
slice
kept
aliv
least
day
prepar
lung
slice
surviv
ex
vivo
condit
assess
whether
influenza
virus
infect
replic
mous
lung
slice
first
lung
slice
differ
thick
gener
determin
optim
thick
lung
slice
suitabl
infect
influenza
virus
expect
thick
slice
produc
infecti
virion
h
postinfect
thick
slice
howev
viru
yield
thick
slice
similar
thick
slice
fig
result
suggest
thick
lung
slice
best
infect
influenza
viru
balanc
cost
effici
next
growth
curv
influenza
virus
mous
lung
slice
obtain
shown
fig
e
hubei
virus
demonstr
timedepend
replic
reach
maximum
titr
h
post
infect
though
viru
titr
ex
vivo
much
lower
cell
cultur
neuraminidas
na
activ
result
fig
c
show
viru
strain
similar
kinet
viru
replic
infect
fig
e
suggest
na
activ
precis
repres
viru
replic
infect
lung
slice
correl
na
activ
viru
titr
ribavirin
test
dose
depend
inhibit
shown
fig
compound
exhibit
dose
depend
inhibit
na
activ
viru
infect
indic
na
activ
use
thick
lung
slice
prepar
bronchoconstrict
observ
day
prepar
untreat
slice
incub
lm
chlorid
min
b
cell
cultur
plate
drug
remov
lung
slice
wash
twice
pb
incub
fresh
cultur
medium
min
c
imag
captur
use
nikon
eclips
ti
invert
microscop
red
blue
black
arrow
show
lung
bronchu
pulmonari
arteri
pulmonari
vein
respect
scale
bar
lm
dh
livedead
stain
assay
lung
slice
stain
calceinam
lm
propidium
iodid
pi
lgml
min
room
temperatur
day
prepar
lower
panel
fh
middl
panel
show
viabl
slice
directli
prepar
slice
complet
loss
activ
treat
e
comparison
calceinam
pi
use
simultan
determin
live
dead
cell
wash
twice
pb
imag
taken
use
nikon
multiphoton
confoc
microscop
mp
excit
nm
emiss
filter
nm
calceinam
nm
pi
scale
bar
lm
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
repres
viru
replic
primari
screen
confirm
infect
lung
slice
influenza
viru
immunofluoresc
assay
ifa
use
stain
nucleoprotein
np
influenza
viru
lung
slice
shown
fig
lung
slice
strongli
infect
influenza
viru
overal
result
demonstr
lung
slice
support
influenza
viru
replic
one
aim
studi
evalu
antiinflammatori
effect
potenti
agent
lung
slice
mani
cytokin
chemokin
elev
influenzainfect
mice
seem
import
influenzainduc
inflamm
despit
complic
cytokin
storm
induc
influenza
viru
infect
chose
eight
import
cytokin
chemokin
belisl
et
al
brand
et
al
lauder
et
al
szretter
et
al
wang
et
al
weiss
et
al
studi
inflammatori
respons
follow
influenza
viru
infect
first
examin
mrna
level
cytokin
chemokin
influenza
virusinfect
lung
slice
real
time
rtpcr
shown
fig
b
exposur
pfuml
dose
hubei
virus
result
elev
mrna
level
cytokin
chemokin
gene
test
h
post
infect
gene
transcript
elev
highli
activ
h
post
infect
cytokin
chemokin
highest
level
induct
transcript
virus
rant
cytokin
chemokin
respons
mediat
two
virus
transcript
level
similar
influenza
viru
use
steadi
protein
level
analysi
determin
protein
level
select
cytokin
chemokin
respons
influenza
viru
infect
h
h
post
infect
shown
fig
exposur
viru
h
protein
level
test
cytokin
chemokin
significantli
elev
except
ifnc
undetect
supernat
lung
slice
fold
increas
mock
tnfa
rant
respect
h
post
infect
higher
level
cytokin
chemokin
induc
fig
fold
increas
respect
highli
stimul
chemokin
h
h
post
infect
consist
result
mrna
respons
viru
infect
taken
togeth
result
suggest
strong
supernat
collect
indic
time
point
perform
na
activ
assay
b
c
tcid
assay
e
f
infect
lung
slice
assess
ifa
assay
slice
thick
lm
expos
pfuml
hubei
virus
h
slice
fix
paraformaldehyd
analys
ifa
imag
captur
use
nikon
multiphoton
confoc
microscop
mp
viru
diluent
use
neg
control
nc
infect
scale
bar
lm
right
panel
show
enlarg
region
interest
left
panel
inflammatori
respons
repres
highli
elev
mrna
protein
level
cytokin
chemokin
trigger
infect
influenza
virus
ex
vivo
mous
lung
slice
result
demonstr
ex
vivo
model
support
influenza
viru
infect
section
exhibit
inflammatori
respons
follow
influenza
viru
infect
section
meet
goal
studi
establish
ex
vivo
mous
slice
model
screen
evalu
antivir
antiinflammatori
drug
influenza
infect
one
assay
ensur
ex
vivo
model
similar
pattern
influenzainduc
cytokin
chemokin
respons
critic
shown
fig
inflammatori
respons
vivo
day
postinfect
appear
robust
cytokinechemokin
level
vivo
day
chosen
compar
ex
vivo
result
mous
studi
show
ifnc
tnfa
exhibit
lower
level
activ
pgml
pgml
pgml
pgml
respect
wherea
rant
exhibit
higher
level
activ
bronchoalveolar
lavag
fluid
balf
pgml
pgml
pgml
pgml
respect
elev
express
test
cytokin
chemokin
supernat
lung
slice
demonstr
express
pattern
compar
mous
model
fig
evalu
correl
ex
vivo
vivo
level
cytokin
chemokin
linear
regress
analysi
model
employ
level
cytokin
chemokin
supernat
lung
slice
h
post
infect
fig
compar
balf
mice
day
post
infect
result
show
posit
correl
ex
vivo
vivo
express
select
cytokin
chemokin
coeffici
correl
fig
specif
rant
perfectli
correl
coeffici
correl
cytokin
chemokin
supernat
lung
slice
h
post
infect
fig
balf
mice
day
post
infect
fig
result
demonstr
ex
vivo
mous
lung
slice
model
resembl
vivo
mous
model
respons
influenza
viru
infect
addit
rant
may
serv
readout
screen
evalu
antiinflammatori
agent
influenza
infect
assess
qualiti
mous
lung
slice
model
use
ribavirin
antivir
drug
refer
pilot
experi
test
z
factor
measur
antivir
antiinflammatori
activ
z
factor
screen
window
coeffici
use
evalu
qualiti
assay
zhang
et
al
neuraminidas
chosen
readout
antivir
activ
confirm
correl
well
product
infecti
virion
fig
chosen
readout
f
nc
hubei
fig
continu
repres
influenza
virusinduc
inflamm
three
reason
exhibit
good
correl
vivo
ex
vivo
model
protein
level
b
highli
induc
chemokin
mous
model
lung
slice
model
c
mice
mice
treat
antibodi
demonstr
global
downregul
cytokin
chemokin
surviv
challeng
lethal
dose
influenza
viru
wang
et
al
therefor
ribavirin
use
determin
na
inhibit
effect
test
perform
lung
slice
model
four
replic
plate
process
determin
z
factor
shown
tabl
z
factor
rang
na
inhibit
inhibit
demonstr
qualiti
lung
slice
model
evalu
antivir
antiinflammatori
effect
satisfactori
valid
mous
lung
slice
model
panel
agent
known
antivir
antiinflammatori
activ
vivo
test
antivir
antiinflammatori
effect
lung
slice
model
among
agent
ribavirin
oseltamivir
gemacron
antiinfluenza
drug
egcg
antivir
antiinflammatori
effect
vivo
antiinflammatori
activ
vivo
show
induc
chang
cytokin
chemokin
place
separ
panel
accord
scale
protein
level
data
point
three
lung
slice
viru
diluent
use
neg
control
comparison
infect
group
neg
control
perform
unpair
ttest
p
p
data
express
mean
sem
nd
detect
realtim
pcr
amplif
detect
cycl
elisa
signal
detect
limit
commerci
kit
agent
report
protect
mice
death
lethal
influenza
infect
shown
tabl
antivir
agent
ribavirin
oseltamivir
gemacron
effici
inhibit
viru
replic
lung
slice
level
decreas
result
inhibit
viral
replic
fig
unexpectedli
oseltamivir
inhibit
viru
replic
lung
slice
without
interf
express
fig
addit
antivir
effect
egcg
possess
antiinflammatori
effect
droebner
et
al
ling
et
al
pinto
et
al
ranjithkumar
et
al
found
egcg
dose
depend
decreas
na
level
level
lung
slice
model
chosen
protect
mice
influenza
infect
antiinflammatori
effect
borgel
et
al
cloutier
et
al
expect
dose
depend
decreas
level
wherea
neither
inhibit
viru
replic
lung
slice
suggest
improv
mous
surviv
antiinflammatori
mechan
fig
valid
model
also
test
six
agent
dicyclomin
clotrimazol
fenofibr
proadifen
benzydamin
nafronyl
oxal
known
antivir
activ
mdck
cell
fail
protect
mice
lethal
dose
influenza
viru
infect
fig
result
show
dicyclomin
clotrimazol
fenofibr
proadifen
benzydamin
inhibit
neither
viral
replic
repres
na
activ
inflammatori
respons
repres
level
mous
lung
slice
fig
howev
nafronyl
oxal
although
show
antivir
activ
inhibit
inflammatori
respons
lm
fig
although
improv
mous
surviv
rate
fig
taken
togeth
result
suggest
benefit
avoid
overus
anim
expens
compound
mous
lung
slice
model
robust
costeffici
screen
evalu
antivir
antiinflammatori
drug
influenza
infect
one
assay
overal
mous
lung
slice
serv
predict
model
efficaci
drug
candid
mous
model
current
antiinfluenza
drug
screen
base
primarili
transform
cell
form
cellbas
assay
though
transform
cell
conveni
high
throughput
screen
vitro
studi
potenc
mechan
distantli
relat
physiolog
patholog
condit
consequ
result
base
transform
cell
may
suffer
simplif
current
treatment
influenza
reli
use
antivir
drug
howev
window
antivir
therapi
narrow
sever
report
shown
antiinflammatori
agent
effect
reduc
death
rate
infect
lethal
influenza
borgel
et
al
cloutier
et
al
comparison
infect
mice
mock
mice
perform
unpair
ttest
p
p
data
express
mean
sem
nd
detect
signal
detect
limit
commerci
kit
b
comparison
cytokin
chemokin
level
respons
influenza
infect
ex
vivo
vivo
model
subtract
correspond
level
mock
group
correl
virusinduc
ifnc
tnfa
rant
balf
day
post
infect
fig
lung
slice
supernat
fig
analys
linear
regress
analysi
model
tabl
pilot
experi
lung
slice
model
use
ribavirin
lm
thick
lung
slice
prepar
describ
section
lung
slice
infect
pfu
ml
viru
h
incub
virus
discard
lung
slice
wash
twice
pb
six
concentr
ribavirin
start
lm
serial
dilut
ad
na
activ
level
cultur
supernat
determin
h
post
infect
describ
section
sbna
b
z
na
c
z
naec
lm
e
lm
f
moreov
current
antivir
drug
screen
perform
primarili
use
cellbas
assay
cellbas
assay
avail
develop
antiinflammatori
agent
influenza
viru
infect
larg
target
singl
host
factor
pathway
play
role
influenzainduc
inflammatori
respons
strategi
could
riski
develop
antiinflammatori
drug
lead
failur
anim
test
clinic
trial
wherea
anim
model
eg
mice
ferret
good
efficaci
studi
antivir
antiinflammatori
drug
timeor
costeffici
overcom
problem
least
part
establish
mous
lung
slice
model
test
drug
antivir
antiinflammatori
activ
one
ex
vivo
assay
conveni
vitro
cellbas
assay
goal
model
follow
mous
slice
remain
aliv
long
enough
effici
influenza
viru
infect
inflammatori
respons
ii
inflammatori
respons
similar
lung
mous
iii
choos
best
readout
antivir
antiinflammatori
activ
model
iv
valid
model
use
antivir
antiinflammatori
agent
confirm
efficaci
vitro
vivo
tissu
viabil
lung
slice
first
concern
establish
lung
slice
model
mous
lung
slice
surviv
maintain
nativ
structur
least
three
day
prepar
sanderson
siminski
et
al
method
monitor
viabil
lung
slice
includ
measur
ldh
releas
ciliari
activ
bronchoconstrict
induc
stimuli
livedead
stain
sanderson
research
result
bronchoconstrict
experi
livedead
stain
experi
demonstr
lung
slice
remain
aliv
least
day
moreov
infect
lung
slice
influenza
virus
kinet
viru
growth
better
indic
mous
lung
slice
stay
viabl
least
first
day
prepar
second
goal
establish
ex
vivo
model
infect
mous
lung
slice
influenza
virus
induct
inflammatori
respons
similar
mous
model
result
demonstr
influenza
virus
replic
effici
mous
lung
slice
result
consist
previou
report
show
influenza
viru
replic
pig
lung
slice
van
pouck
et
al
ifa
mous
lung
slice
clearli
shown
infect
influenza
viru
analys
inflammatori
respons
lung
slice
follow
infect
influenza
viru
measur
level
cytokin
chemokin
compar
balf
mice
result
show
posit
correl
exist
ex
vivo
vivo
model
express
select
cytokin
chemokin
coeffici
correl
ifnc
significantli
induc
vivo
ex
vivo
may
due
influx
multipl
type
immun
cell
lung
vivo
lung
slice
lower
level
lung
slice
may
due
observ
epitheli
cell
macrophag
secret
less
neutrophil
respond
influenza
infect
brand
et
al
observ
ifnc
secret
detect
lung
slice
explain
fact
primari
sourc
ifnc
nk
cell
cell
cell
schroder
et
al
absent
lung
slice
despit
discrep
cytokin
chemokin
respons
rant
perfectli
correl
ex
vivo
vivo
model
therefor
rant
may
repres
inflammatori
respons
follow
influenza
viru
infect
ex
vivo
model
choic
readout
antivir
effect
straight
forward
determin
previous
lab
fluorometr
substrat
neuraminidas
influenza
viru
munana
use
detect
viru
neuraminidas
activ
repres
level
viru
replic
viru
replic
level
determin
na
activ
proport
tcid
shown
fig
compar
howev
choic
readout
antiinflammatori
activ
much
complic
known
cytokin
chemokin
wide
accept
repres
inflammatori
respons
influenza
infect
base
comparison
ex
vivo
vivo
respons
select
cytokin
chemokin
follow
influenza
viru
infect
rant
may
serv
readout
influenzainduc
inflamm
recent
literatur
elucid
cytokin
chemokin
import
influenzainduc
innat
immun
respons
cytokin
receptor
gene
knock
mice
gmcsf
mice
surviv
influenza
infect
howev
mice
surviv
influenza
infect
suggest
may
play
tabl
evalu
panel
antivir
antiinflammatori
agent
mous
lung
slice
model
lm
thick
lung
slice
prepar
describ
section
slice
infect
pfuml
viru
h
incub
virus
remov
lung
slice
wash
twice
pb
drug
serial
dilut
concentr
ad
maintain
h
na
activ
level
determin
describ
section
import
role
aberr
cytokin
respons
influenza
infect
darwish
et
al
wang
et
al
also
propos
poor
prognost
indic
patient
sever
acut
respiratori
syndrom
sar
clinic
similar
sever
influenza
infect
nelli
et
al
although
compar
proteom
chang
induc
influenza
rational
choos
singl
factor
prove
concept
previous
report
cameron
et
al
take
result
consider
chose
readout
evalu
antiinflammatori
drug
appear
valid
repres
inflammatori
respons
valid
test
panel
antivir
antiinflammatori
agent
cours
critic
studi
efficaci
candid
compound
requir
multipl
readout
determin
level
multipl
cytokin
chemokin
use
assess
inhibitori
effect
inflammatori
respons
follow
influenza
viru
infect
often
compound
show
antivir
antiinflammatori
activ
singl
cell
system
fail
anim
assay
valid
precis
cut
mous
lung
slice
model
screen
evalu
antivir
antiinflammatori
drug
influenza
viru
infect
one
assay
use
na
readout
four
categori
known
antivir
antiinflammatori
drug
test
antivir
antiinflammatori
activ
result
compar
mous
studi
conduct
other
us
four
categori
agent
agent
antivir
effect
vitro
vivo
ii
agent
antivir
antiinflammatori
effect
vitro
vivo
iii
agent
antiinflammatori
effect
vitro
vivo
iv
agent
antivir
effect
vitro
fail
mous
model
agent
first
three
categori
show
antivir
antiinflammatori
effect
lung
slice
model
among
agent
categori
iv
fail
show
antivir
antiinflammatori
activ
mous
lung
slice
model
except
nafronyl
oxal
shown
inhibit
releas
overal
valid
test
group
agent
known
antivir
antiinflammatori
activ
demonstr
mous
lung
slice
model
valid
conveni
costeffici
screen
evalu
antivir
antiinflammatori
drug
one
ex
vivo
assay
appear
drug
show
either
antivir
antiinflammatori
activ
mous
lung
slice
model
may
protect
mice
infect
lethal
influenza
though
except
may
occur
summari
establish
valid
mous
lung
slice
model
evalu
compound
antivir
antiinflammatori
effect
one
assay
importantli
employ
lung
slice
model
econom
term
experi
cost
compound
synthesi
anim
use
develop
antivir
drug
mous
lung
slice
model
similar
mous
model
develop
antiinflammatori
drug
mous
lung
slice
model
suitabl
drug
target
multipl
target
pathway
involv
inflammatori
respons
follow
influenza
infect
similar
mous
model
model
use
secondari
screen
select
drug
candid
potent
antivir
antiinflammatori
activ
test
anim
model
notabl
mous
lung
slice
model
use
caution
test
antiinflammatori
drug
influenza
virus
two
aspect
firstli
make
sure
viru
test
replic
effici
mous
lung
slice
induc
cytokinechemokin
respons
similar
vivo
secondli
readout
inflammatori
respons
differ
determin
experiment
ex
vivo
vivo
consid
infect
mani
respiratori
virus
caus
acut
inflamm
human
lung
induc
similar
inflammatori
respons
like
antiinflammatori
drug
develop
use
influenza
viru
infect
mous
lung
slice
model
may
also
effect
treatment
infect
respiratori
virus
taken
togeth
research
demonstr
benefici
use
mous
lung
slice
model
develop
new
drug
either
antivir
antiinflammatori
activ
treatment
influenza
viru
infect
